ClinicalTrials.gg
CompletedNCT06780306Updated Feb 11, 2026

A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03.

A Phase 2 interventional study of TTAX03 and Saline (NaCl 0,9 %) (placebo) in Dry Eye, Dry Eye Disease (DED) and Dry Eye Disease With Severe Keratitis, sponsored by BioTissue Holdings, Inc. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by BioTissue Holdings, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Enrollment
218th of 473
74 · median 60
Started
2024
with 31 others
Phase 2
97 of 544
5 open now
Registered
481st of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 218th largest by enrollment of the 473 interventional ones that give a count, is one of 32 that started in 2024, is one of 97 in phase 2, and was the 481st registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

The purpose of this randomized, controlled, multicenter study is to evaluate the safety and efficacy of TTAX03 in participants with mild to moderate DED.

The primary question it aims to answer is if TTAX03 is safe. The secondary is the effectiveness.

Researchers will compare 10mg of TTAX03 reconstituted in 150, 300, or 600 uL saline to the saline control group to look at effectiveness.

Participants will be randomized to a treatment group one time and be evaluated at 5 different study visits.

Read the detailed description

The purpose of this randomized, controlled, multicenter study is to evaluate the safety and efficacy of TTAX03 in participants with mild to moderate DED. After confirmation of inclusion and exclusion criteria, all eligible patients will be randomized in a 1:1:1:1 ratio to receive one of the three doses of TTAX03 (10 mg of TTAX03 reconstituted in 150, 300, or 600 uL saline, i.e., subgroup A, B, and C, respectively) or to the saline control group (subgroup D). For all four groups, the same volume of reconstituted solution will be applied into the concave bowl of a bandage contact lens and inserted into the eye. The more severe eye will serve as the study eye, which meets inclusion and exclusion criteria. The treatment period is 5 days of continuous bandage contact lens wear. Safety follow-up without further treatment will continue for twelve weeks. After baseline (day 1) and completion of treatment, enrolled patients will be evaluated for safety and efficacy at Day 6 ± 1, Day 29 ± 3, Day 57 ± 3, and Day 85 ± 3.

03

Conditions studied

  • Dry Eye
  • Dry Eye Disease (DED)
  • Dry Eye Disease With Severe Keratitis

Browse trials for

Keywords

  • Dry Eye Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old.
  2. Provision of signed and dated form.
  3. Baseline VAS Dryness score ≥40
  4. Baseline Ocular Surface Disease Index (OSDI) score ≥ 13.
  5. Baseline corneal fluorescein staining with a total score ≥ 4 but ≤13, and ≥ 2 in at least one region, by the NEI Grading System† in the study eye.
  6. In the opinion of the investigator, the participant can follow oral and written instructions.
  7. In the opinion of the investigator, the participant can complete all study procedures and visits.

Exclusion criteria

Exclusion Criteria:

  1. Has a corneal ectatic disorder or other ocular surface disease such as limbal stem cell deficiency or a cicatricial component (e.g., symblepharon, fornix foreshortening and lid margin/lashes abnormality) caused for example by oGVHD, irradiation, chemical burns, trachoma, Stevens Johnson syndrome/toxic epidermal necrolysis, ocular cicatricial pemphigoid, or the destruction of conjunctival goblet cells (as with vitamin A deficiency).
  2. Has severe blepharitis or severe obvious inflammation of the lid margin.
  3. Has severe conjunctivochalasis.
  4. Has nocturnal exposure e.g. incomplete closure or lagophthalmos or floppy eyelid.
  5. Has epithelial basement membrane dystrophy (i.e., map-dot-fingerprint dystrophy) or history of recurrent corneal erosion
  6. Has neuropathic corneal pain
  7. Has a sunken globe (due to the reduction or loss of orbital fat)
  8. Has severe DED per corneal fluorescein staining with a total score ≥ 13by the NEI Grading System in either eye.
  9. Prior history of intolerance or adverse events using BCL.
  10. Have had dissolvable or temporary plug(s) (including hydrogel or Lacrifill®) inserted within 6 months prior to screening.
  11. Is using a nasal cholinergic agonist such as Tyrvaya in the last 30 days.
  12. Has had previous ocular surgery in the study eye within the past 12 weeks.
  13. Plans to use autologous serum drops during the study period in either eye.
  14. Has elevated intraocular pressure >21mmHg in either eye requiring topical therapy.
  15. Is currently using or plans to use topical glaucoma medication in either eye.
  16. Has a known allergy to topical ophthalmic sodium fluorescein dye.
  17. Has a known intolerance to unbuffered normal saline.
  18. Prior adverse events of using human birth tissue product.
  19. Is currently incarcerated or anticipates possible incarceration during the time course of this study.
  20. Has tested positive for COVID-19 within 28 days prior to screening.
  21. Is currently participating in any other type of eye-related clinical or research study that in the opinion of the investigator would confound or would risk confounding study results.
  22. Has a condition or is in a situation which, in the investigator's opinion, may put the participant at significant risk, may confound study outcomes, or may significantly interfere with the participant's participation in the study.
  23. Prior amniotic membrane product used for dry eye therapy in the study eye in the past 6 months.
  24. Has Strabismus (squint/crossed eyes) or Amblyopia (lazy eye).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    10mg TTAX03 reconstituted in 150 uL saline

    For all four groups, 100 mL of reconstituted solution will be applied into the concave bowl of a bandage contact lens and inserted into the study eye.

    Biological: TTAX03

  • Active comparator
    10mg TTAX03 reconstituted in 300 uL saline

    For all four groups, 100 mL of reconstituted solution will be applied into the concave bowl of a bandage contact lens and inserted into the study eye.

    Biological: TTAX03

  • Active comparator
    10mg TTAX03 reconstituted in 600 uL saline

    For all four groups, 100 mL of reconstituted solution will be applied into the concave bowl of a bandage contact lens and inserted into the study eye.

    Biological: TTAX03

  • Placebo comparator
    300 uL of saline

    For all four groups, 100 mL of reconstituted solution will be applied into the concave bowl of a bandage contact lens and inserted into the study eye.

    Biological: Saline (NaCl 0,9 %) (placebo)

Interventions

  • BiologicalTTAX03

    Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord

  • BiologicalSaline (NaCl 0,9 %) (placebo)

    300 mL Sterile, preservative free 0.9% NaCl

06

What researchers measure

Primary outcomes

  1. Determine 12 week ocular and general safety after application of TTAX03.

    Incidence and nature of treatment emergent adverse events (TEAE) between TTAX03 and saline.

    Time frame: 12 weeks

Secondary outcomes

  1. Proportion of participants who show complete resolution of superficial punctate keratopathy, i.e., absence of corneal fluorescein staining, on Day 6 by group.

    Determine the relationship between TTAX03 doses and efficacy per changes from baseline in complete resolution of superficial punctate keratopathy (defined by corneal fluorescein staining) at Day 6 when compared to the saline control.

    Time frame: Day 6

  2. Mean change from baseline to Day 6 in corneal fluorescein staining (National Eye Institute (NEI) score) by group.

    Examine the relationship between TTAX03 doses and changes from baseline in corneal epithelial staining at Day 6 when compared to the saline control.

    Time frame: Baseline to Day 6

  3. Proportion of participants with clinically meaningful reduction in corneal fluorescein staining (NEI ≥ 3) from baseline to Day 6 by group.

    Examine the relationship between TTAX03 doses and clinically meaningful changes from baseline vs. saline in corneal staining during the follow up to 12 weeks.

    Time frame: Baseline to Day 6

  4. Proportion of participants with clinically meaningful reduction in corneal fluorescein staining (NEI ≥ 3) from baseline to Day 29 by group.

    Examine the relationship between TTAX03 doses and clinically meaningful changes from baseline vs. saline in corneal staining during the follow up to 12 weeks.

    Time frame: Baseline to Day 29

  5. Proportion of participants with clinically meaningful reduction in corneal fluorescein staining (NEI ≥ 3) from baseline to Day 57 by group.

    Examine the relationship between TTAX03 doses and clinically meaningful changes from baseline vs. saline in corneal staining during the follow up to 12 weeks.

    Time frame: Baseline to Day 57

  6. Proportion of participants with clinically meaningful reduction in corneal fluorescein staining (NEI ≥ 3) from baseline to Day 85 by group.

    Examine the relationship between TTAX03 doses and clinically meaningful changes from baseline vs. saline in corneal staining during the follow up to 12 weeks.

    Time frame: Baseline to Day 85

  7. Mean change in dry eye symptoms (measured by OSDI) from baseline on Day 6 by group.

    Examine the relationship between TTAX03 doses and change of dry eye symptoms from baseline when compared to saline at Day 6.

    Time frame: Baseline to Day 6

  8. Mean change in dry eye symptoms (measured by VAS) from baseline on Day 6 by group.

    Examine the relationship between TTAX03 doses and change of dry eye symptoms from baseline when compared to saline at Day 6.

    Time frame: Baseline to Day 6

  9. Mean change from baseline in BCVA (logMAR) measured by ETDRS chart on Day 6 by group.

    Examine the relationship between TTAX03 doses and change of best corrected visual acuity (BCVA) from baseline when compared to saline at Day 6.

    Time frame: Baseline to Day 6

  10. Proportion of participants who show complete resolution of superficial punctate keratopathy, i.e., absence of corneal fluorescein staining, on Day 29 by group.

    Examine the relationship between TTAX03 doses and percentages of participants showing complete resolution of corneal staining from baseline when compared to saline during the follow up 12 weeks.

    Time frame: Day 29

  11. Proportion of participants who show complete resolution of superficial punctate keratopathy, i.e., absence of corneal fluorescein staining, on Day 57 by group.

    Examine the relationship between TTAX03 doses and percentages of participants showing complete resolution of corneal staining from baseline when compared to saline during the follow up 12 weeks.

    Time frame: Day 57

  12. Proportion of participants who show complete resolution of superficial punctate keratopathy, i.e., absence of corneal fluorescein staining, on Day 85 by group.

    Examine the relationship between TTAX03 doses and percentages of participants showing complete resolution of corneal staining from baseline when compared to saline during the follow up 12 weeks.

    Time frame: Day 85

  13. Mean change from baseline in corneal fluorescein staining (National Eye Institute (NEI) score) on Day 29 by group.

    Examine the relationship between TTAX03 doses and change of corneal epithelial staining from baseline between when compared to saline during the follow up to 12 weeks.

    Time frame: Baseline to Day 29

  14. Mean change from baseline in corneal fluorescein staining (National Eye Institute (NEI) score) on Day 57 by group.

    Examine the relationship between TTAX03 doses and change of corneal epithelial staining from baseline between when compared to saline during the follow up to 12 weeks.

    Time frame: Baseline to Baseline to Day 57

  15. Mean change from baseline in corneal fluorescein staining (National Eye Institute (NEI) score) on Day 85 by group.

    Examine the relationship between TTAX03 doses and change of corneal epithelial staining from baseline between when compared to saline during the follow up to 12 weeks.

    Time frame: Baseline to Baseline to Day 85

  16. Mean change in dry eye symptoms (measured by OSDI) from baseline on Day 29 by group.

    Examine the relationship between TTAX03 doses and change of ocular dry eye symptoms from baseline when compared to saline during the follow up to 12 weeks.

    Time frame: Baseline to Day 29

  17. Mean change in dry eye symptoms (measured by OSDI) from baseline on Day 57 by group.

    Examine the relationship between TTAX03 doses and change of ocular dry eye symptoms from baseline when compared to saline during the follow up to 12 weeks.

    Time frame: Baseline to Day 57

  18. Mean change in dry eye symptoms (measured by OSDI) from baseline on Day 85 by group.

    Examine the relationship between TTAX03 doses and change of ocular dry eye symptoms from baseline when compared to saline during the follow up to 12 weeks.

    Time frame: Baseline to Day 85

  19. Mean change in dry eye symptoms (measured by VAS) from baseline on Day 29 by group.

    Examine the relationship between TTAX03 doses and change of ocular dry eye symptoms from baseline when compared to saline during the follow up to 12 weeks.

    Time frame: Baseline to Day 29

  20. Mean change in dry eye symptoms (measured by VAS) from baseline on Day 57 by group.

    Examine the relationship between TTAX03 doses and change of ocular dry eye symptoms from baseline when compared to saline during the follow up to 12 weeks.

    Time frame: Baseline to Day 57

  21. Mean change in dry eye symptoms (measured by VAS) from baseline on Day 85 by group.

    Examine the relationship between TTAX03 doses and change of ocular dry eye symptoms from baseline when compared to saline during the follow up to 12 weeks.

    Time frame: Baseline to Day 85

  22. Mean change from baseline in BCVA (logMAR) measured by ETDRS chart on Days 29 by group.

    Examine the relationship between TTAX03 doses and change of BCVA from baseline when compared to saline during the follow up to 12 weeks.

    Time frame: Day 29

  23. Mean change from baseline in BCVA (logMAR) measured by ETDRS chart on Day 57 by group.

    Examine the relationship between TTAX03 doses and change of BCVA from baseline when compared to saline during the follow up to 12 weeks.

    Time frame: Day 57

  24. Mean change from baseline in BCVA (logMAR) measured by ETDRS chart on Day 85 by group.

    Examine the relationship between TTAX03 doses and change of BCVA from baseline when compared to saline during the follow up to 12 weeks.

    Time frame: Day 85

07

Study locations

9 sites
  • University California Berkeley
    Berkeley, California 94720, United States
  • Advanced Research, LLC.
    Deerfield Beach, Florida 33064, United States
  • Southwest Eye Care
    Chaska, Minnesota 55318, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Eye Associates of North Jersey
    Dover, New Jersey 07801, United States
  • Northern New Jersey Eye Institute
    South Orange, New Jersey 07079, United States
  • Wilmington Eye at Brunswick Forest
    Leland, North Carolina 28451, United States
  • CORE, Inc. / Vita Eye Clinic
    Shelby, North Carolina 28150, United States
  • Westlake Eye Specialists
    Austin, Texas 78749, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Jan 2026, 13 months.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 13 months is above that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2025
First posted
Jan 17, 2025
StartActual
Dec 12, 2024
Primary completionActual
Jan 30, 2026
CompletionActual
Jan 30, 2026
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06780306
Lead sponsor
BioTissue Holdings, Inc
Responsible party
Sponsor
First posted
Jan 17, 2025
Start date
Dec 12, 2024
Primary completion
Jan 30, 2026
Completion
Jan 30, 2026
Last update
Feb 11, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TTAX-03

Start the discussion